| Gene symbol | C5 | Synonyms | C5D, C5a, C5b, CPAMD4, ECLZB | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.2 | dbXrefs | |
| Description | complement C5 | ||||
| GTO ID | GTC0567 |
| Trial ID | NCT05571267 |
| Disease | Macular Degeneration |
| Altered gene | C5 |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | ARC1905|Zimura|Avacincaptad Pegol |
| Co-treatment | Avastin |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | A Phase 2A Randomized Open-Label Controlled Trial to Assess the Safety of Zimura (Anti-C5 Aptamer) Administered in Combination With Anti-VEGF Therapy in Treatment Experienced Patients With Neovascular Age-Related Macular Degeneration |
| Year | 2022 |
| Country | United States |
| Company sponsor | IVERIC bio, Inc. |
| Other ID(s) | OPH2004 |
| Cohort1: ARC1905_Avastin | |||||||||||
|
|||||||||||
| Cohort2: ARC1905_Lucentis | |||||||||||
|
|||||||||||
| Cohort3: ARC1905_Eylea | |||||||||||
|
|||||||||||